

20. Thompson RH, Atwell T, Schmit G, et al. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. *Eur Urol*. 2015; 67(2): 252–259.
21. Johnson BA, Sorokin I, Cadeddu JA. Ten-Year Outcomes of Renal Tumor Radio Frequency Ablation. *J Urol*. 2019; 201(2): 251–258.
22. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. *Cancer*. 2008; 113(10): 2671–2680.
23. Zhou W, Herwald SE, McCarthy C, Uppot RN, Arellano RS. Radiofrequency Ablation, Cryoablation, and Microwave Ablation for T1a Renal Cell Carcinoma: A Comparative Evaluation of Therapeutic and Renal Function Outcomes. *J Vasc Interv Radiol*. 2019; 30(7): 1035–1042.
24. Ahrar K, Matin S, Wood CG, et al. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. *J Vasc Interv Radiol*. 2005; 16(5): 679–688.
25. Pierorazio PM, Hyams ES, Mullins JK, Allaf ME. Active surveillance for small renal masses. *Rev Urol*. 2012; 14(1–2): 13–9.
26. Ray S, Cheaib JG, Pierorazio PM. Active Surveillance for Small Renal Masses. *Rev Urol*. 2020; 22(1): 9–16.
27. Mir MC, Capitanio U, Bertolo R, et al. Role of Active Surveillance for Localized Small Renal Masses. *Eur Urol Oncol*. 2018; 1(3): 177–187.
28. Smaldone MC, Kutikov A, Egleston BL, et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. *Cancer*. 2012; 118(4): 997–1006.
29. Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. *Eur Urol*. 2015; 68(3): 408–415.
30. Sebastià C, Corominas D, Musquera M, et al. Active surveillance of small renal masses. *Insights Imaging*. 2020; 11(1): 63.
31. Rebez G, Pavan N, Mir MC. Available active surveillance follow-up protocols for small renal mass: a systematic review. *World J Urol*. 2021; 39(8): 2875–2882.
32. Finelli A, Ismaila N, Bro B, et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017; 35(6): 668–680.
33. Crispen PL, Viterbo R, Fox EB, et al. Delayed intervention of sporadic renal masses undergoing active surveillance. *Cancer*. 2008; 112(5): 1051–1057.
34. Finelli A, Cheung DC, Al-Matar A, et al. Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort. *Eur Urol*. 2020; 78(3): 460–467.
35. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol*. 1994; 47(11): 1245–1251.
36. Kutikov A, Egleston BL, Canter D, et al. Competing risks of death in patients with localized renal cell carcinoma: a comorbidity based model. *J Urol*. 2012; 188(6): 2077–2083.
37. Sammon JD, Pucheril D, Abdollah F, et al. Preventable mortality after common urological surgery: failing to rescue? *BJU Int*. 2015; 115(4): 666–674.
38. Ferraris VA, Bolanos M, Martin JT, Mahan A, Saha SP. Identification of patients with postoperative complications who are at risk for failure to rescue. *JAMA Surg*. 2014; 149(11): 1103–1108.
39. American College of Surgeons National Surgical Quality Improvement Program. Surgical Risk Calculator [online]. © 2007–2022 [cit. 2022-01-10]. Dostupné z: <http://www.riskcalculator.facs.org/RiskCalculator/>.